The US medical devices industry saw a drop of 19% in overall deal activity during September 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 64 deals worth $1.11bn were announced in September 2019, compared to the 12-month average of 79 deals.
Venture financing was the leading category in the month in terms of volume with 45 deals which accounted for 70.3% of all deals.
In second place was M&A with 17 deals, followed by private equity with two transactions, respectively accounting for 26.6% and 3.1% of overall deal activity in the country’s medical devices industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $768.94m, while venture financing and private equity deals totalled $293.73m and $45m, respectively.
US medical devices industry deals in September 2019: Top deals
The top five medical devices industry deals accounted for 74.5% of the overall value during September 2019.
The combined value of the top five medical devices deals stood at $825m, against the overall value of $1.11bn recorded for the month.
The top five medical devices industry deals of September 2019 tracked by GlobalData were:
1) Stryker’s $500m acquisition of GYS Tech and Mobius Imaging
2) The $230m acquisition of Cheetah Medical by Baxter International
3) Bayer’s $40m venture financing of Informed Data Systems
4) The $30m private equity deal with Skincure Oncology by Seacoast Capital Managers
5) OncoCyte’s acquisition of Razor Genomics for $25m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.